Articles On Dimerix (ASX:DXB)

Special Report: Biotech Dimerix wins over institutional investors as it prepares for a global Phase 3 COVID-19 trial. Hotshot biotech Dimerix (ASX:DXB) is finally on the radar of institutional investors, who bought in for the first time via...

On Stockhead today, how a ‘tired’ gold mine transformed shell company Bellevue into a $650m market darling, cobalt has stumbled this year but EV growth is expected to drive demand and prices and is this a new dawn for nickel? But first…   T...

Drug discovery tearaway Dimerix – which is trading up more than 200 per cent in the past six months – is making a trip to equity capital markets. 

Special Report: Dimerix expects results for its FSGS clinical trial in July and says so far, it’s meeting the primary endpoint.    Biotech Dimerix has dosed its last patient in a crucial phase 2a clinical trial on focal segmental glomerulos...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The market...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 134-odd small cap health stocks and of those which were trading on Wednesday, 71 were in positive territory over the last fortnight, 11 were flat and 52 saw...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

A quick wrap of the key winners and losers on Thursday, June 4. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day.   Code Name Price % Chg...

A lead drug candidate developed by clinical-stage biopharmaceutical company Dimerix Limited (ASX: DXB) has been selected for inclusion in a global study aimed at treating patients with acute respiratory distress syndrome as a result of COVI...

The Dimerix Ltd (ASX: DXB) share price has raced out of the gates this morning following news that one of its treatments has been included in a global COVID-19 clinical study. Dimerix is a clinical-stage biopharmaceutical company that deve...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Special Report: Dimerix’s key drug has been selected for a global trial looking at COVID-19 treatments. Biotech Dimerix’s (ASX: DXB) key drug candidate will be used in a global program aimed at treating patients who have Acute Respiratory...

Dimerix (ASX:DXB) has announced that its DMX-200 has been selected for inclusion in the protocol as a new treatment arm in a clinical trial for Acute Respiratory Distress Syndrome as a result of COVID-19.

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Markets be...

Special Report: Drug developer Dimerix hasn’t been affected by the March market rout and since April has surged. What is behind this push? Shares in drug developer Dimerix (ASX:DXB) have doubled in value in the last six months and the stock...

Neuren Pharmaceuticals (ASX: NEU) is getting interesting results from a mouse trial of a treatment for Phelan-McDermid syndrome (PMS), a rare genetic illness which exhibits symptoms of conditions including autism and epilepsy. The study fou...

Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) received an operational boost earlier today after announcing that patients from phase 2 trials will continue treatment with its DMX-200 adjunct therapy under Australia’s Therapeuti...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 136-odd small cap health stocks, 47 saw their share prices fall, 67 improved and 22 were flat. >> Scroll down for a table showing the performance of s...

Biopharmaceutical company Dimerix (DXB) has announced the outcomes for its phase 2 clinical trials in treating patients with its DMX-200 receptor blocker The Committee did not find any safety concerns in patients administered with DMX-200...

You don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the most complicated mysteries still to be solved today: the human body. Biotech CEOs and chairs tend to be the cross-over scientists. However,...

Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusBiotech event in Melbourne. In this episode Tim chats with CEO and MD of Dimerix, Nina Webster, and CEO of Pharmaxis, Gary Phillips. Dimerix...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

A Larger Pipeline Dimerix have diversified their drug pipeline by discovering DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). What is COPD? COPD is the fourth-leading cause of death in the world and although treatments exist to im...

Special Report: The inaugural Biotech Luncheon in Perth launched with a bang, with more than 150 guests attending the event last week. Hosted by industry entrepreneur Brian Leedman, the luncheon was established to raise awareness of, and bu...

Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) has announced plans to target the development of what it calls “an important new discovery” in the treatment of chronic obstructive pulmonary disease (COPD). The DMX-700 drug was i...

When it comes to the listed biotech space, getting the communication right is critical. For starters, it’s a sector geared around medical breakthroughs  usually based highly complex science. And for investors and market analysts, the outcom...

The WA investment community will turn its attention to healthcare next Thursday, when the annual Biotech Lunch takes place in Perth. Hosted by industry entrepreneur Brian Leedman, the luncheon will provide a forum for brokers and investors...

Dimerix Limited (ASX: DXB) Clinical-stage biopharmaceutical company, Dimerix Limited (ASX: DXB) is engaged in developing new therapies for the unmet requirements of the medicine market all over the world. On 26 June 2019, Dimerix announced...